Page 35 - Škrgat, Sabina, ed. 2022. Severe Asthma - Basic and Clinical Views. Koper: University of Primorska Press. Severe Asthma Forum, 1

Lundback B, Alexander M, Day J, et
al. Evaluation of fluticasone propionate
(500 micrograms day-1) administered
either as dry powder via a Diskhaler in-
haler or pressurized inhaler and com-
pared with beclomethasone dipropion-
ate (1000 micrograms day-1) admin-
istered by pressurized inhaler. Respir 58.
Med. 1993 Nov;87(8):609-20.
51. Bernstein DI, Berkowitz RB, Chervin-
sky P, et al. Dose-ranging study of a
new steroid for asthma: mometasone
furoate dry powder inhaler. Respir 59.
Med. 1999 Sep;93(9):603-12.
52. Kemp J P, Berkowitz RB, Miller SD,
et al. Mometasone furoate admin-
istered once daily is as effective as 60.
twice-daily administration for treat-
ment of mild-to-moderate persistent
asthma. J Allergy Clin Immunol. 2000
Sep;106(3):485-92. 61.
53. Manning P, Gibson PG, Lasser-
son, TJ. Ciclesonide versus placebo
for chronic asthma in adults and chil- 62.
dren. Cochrane Database Syst Rev.
2008 Apr 16;2008(2):CD006217. doi:
10.1002/14651858.CD006217.pub2.
54. Taylor DA, Jensen MW, Kanabar V, et
al. A dose-dependent effect of the nov-
el inhaled corticosteroid ciclesonide 63.
on airway responsiveness to adeno-
sine-5’-monophosphate in asthmat-
ic patients. Am J Respir Crit Care Med.
1999 Jul;160(1):237-43.
55. Postma DS, Sevette C, Martinat J, et
al. Treatment of asthma by the inhaled 64.
corticosteroid ciclesonide given either in
the morning or evening. Eur Respir J.
2001 Jun;17(6):1083-8.
56. van den Berge M, Luijk B, Bareille P, et
al. Prolonged protection of the new in-
haled corticosteroid fluticasone furo-
ate against AMP hyperresponsiveness
in patients with asthma. Allergy. 2010
Dec;65(12):1531-5.
57. Laitinen, LA, Laitinen, A, Haahte-
la TA. comparative study of the effects
of an inhaled corticosteroid, budeso- 35
nide, and a beta 2-agonist, terbutaline,
on airway inflammation in newly di- the story of corticosteroids in asthma
agnosed asthma: a randomized, dou-
ble-blind, parallel-group controlled
trial. J Allergy Clin Immunol. 1992
Jul;90(1):32-42.
Haahtela T, Järvinen M, Kava T, et al.
Comparison of a beta 2-agonist, terbu-
taline, with an inhaled corticosteroid,
budesonide, in newly detected asthma.
N Engl J Med. 1991 Aug 8;325(6):388-
92.
Haahtela T, Järvinen M, Kava T, et
al. Effects of reducing or discontinu-
ing inhaled budesonide in patients with
mild asthma. N Engl J Med. 1994 Sep
15;331(11):700-5.
Chu EK, Drazen JM. Asthma: one
hundred years of treatment and on-
ward. Am J Respir Crit Care Med.
2005 Jun 1;171(11):1202-8.
Suissa S, Ernst P, Benayoun S, et al.
Low-dose inhaled corticosteroids and
the prevention of death from asthma. N
Engl J Med. 2000 Aug 3;343(5):332-6.
Greening AP, Ind PW, Northfield M, et
al. Added salmeterol versus higher-dose
corticosteroid in asthma patients with
symptoms on existing inhaled corti-
costeroid. Allen & Hanburys Limit-
ed UK Study Group. Lancet. 1994 Jul
23;344(8917):219-24.
Pauwels RA, Löfdahl CG, Postma DS,
et al. Effect of inhaled formoterol and
budesonid on exacerbations of asthma.
Corticosteroids Establishing Therapy
(FACET) International Study Group. N
Engl J Med. 1997 Nov 13;337(20):1405-
11.
Bateman ED, Boushey HA, Bousquet
J, et al. Can guideline-defined asth-
ma control be achieved? The Gain-
ing Optimal Asthma ControL study.
Am J Respir Crit Care Med. 2004 Oct
15;170(8):836-44.